EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis

Breast Cancer Research and Treatment

Volumn 138, Issue 3, 2013, Pages 741-752

  Moore, Heather M ^a,b   Gonzalez, Maria E ^a,b   Toy, Kathy A ^a,b   Cimino Mathews, Ashley ^c   Argani, Pedram ^c   Kleer, Celina G ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Breast cancer; Cell motility; EZH2; Metastasis; p38; Snail

Indexed keywords

EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYCOMB REPRESSIVE COMPLEX 2; SUZ12 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG METASTASIS; MESENCHYME CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; POLYCOMB REPRESSIVE COMPLEX 2; SIGNAL TRANSDUCTION;

EID: 84877836496     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2498-x     Document Type: Article

References (46)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53(1):5-26
2. American Cancer Society (2012) Breast cancer facts and figures 2011-2012. American Cancer Society, Atlanta
3. Hayes DF, Isaacs C, Stearns V (2001) Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 6(4):375-392
4. Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A, Popkin D, Pillus L, Jenuwein T (1997) Mammalian homologues of the Polycomb-group gene enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 16(11):3219-3232. doi: 10.1093/emboj/16.11.3219
5. Ringrose L, Paro R (2004) Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 38:413-443. doi: 10.1146/annurev.genet.38.072902.091907
6. Satijn DP, Otte AP (1999) Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochim Biophys Acta 1447(1):1-16 S0167-4781(99)00130-X
7. Tonini T, Bagella L, D'Andrilli G, Claudio PP, Giordano A (2004) Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 23(28):4930-4937. doi: 10.1038/sj.onc.1207608
8. Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, Sun L, Zhang Y, Chen Y, Li R, Hong M, Shang Y (2007) Integration of estrogen and Wnt signaling circuits by the Polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 27(14):5105-5119. doi: 10.1128/MCB.00162-07
9. Su IH, Dobenecker MW, Dickinson E, Oser M, Basavaraj A, Marqueron R, Viale A, Reinberg D, Wulfing C, Tarakhovsky A (2005) Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121(3):425-436. doi: 10.1016/j.cell.2005.02.029
10. Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, Mehra R, Lonigro RJ, Siddiqui J, Palanisamy N, Wu YM, Cao X, Kim JH, Zhao M, Qin ZS, Iyer MK, Maher CA, Kumar-Sinha C, Varambally S, Chinnaiyan AM (2012) Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell. doi: 10.1016/j.molcel.2012.10.008
11. Chang CJ, Hung MC (2012) The role of EZH2 in tumour progression. Br J Cancer 106(2):243-247. doi: 10.1038/bjc.2011.551
12. Sauvageau M, Sauvageau G (2010) Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7(3):299-313. doi: 10.1016/j.stem.2010.08.002
13. Chase A, Cross NC (2011) Aberrations of EZH2 in cancer. Clin Cancer Res 17(9):2613-2618. doi: 10.1158/1078-0432.CCR-10-2156
14. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100(20):11606-11611. doi: 10.1073/pnas.1933744100
15. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24(2):268-273. doi: 10.1200/JCO.2005.01.5180
16. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA (2006) Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12(4):1168-1174. doi: 10.1158/1078-0432.CCR-05-1533
17. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD, Kleer CG (2009) Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 28(6):843-853. doi: 10.1038/onc.2008.433
18. Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG (2006) Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 66(8):4095-4099. doi: 10.1158/0008-5472.CAN-05-4300
19. Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9(8):537-549. doi: 10.1038/nrc2694
20. del Barco Barrantes I, Nebreda AR (2012) Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans 40(1):79-84. doi: 10.1042/BST20110676
21. Rosenthal DT, Iyer H, Escudero S, Bao L, Wu Z, Ventura AC, Kleer CG, Arruda EM, Garikipati K, Merajver SD (2011) p38gamma promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior. Cancer Res 71(20):6338-6349. doi: 10.1158/0008-5472.CAN-11-1291
22. Kleer CG, Zhang Y, Pan Q, Merajver SD (2004) WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. Neoplasia 6(2):179-185. doi: 10.1593/neo.03316
23. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Kleer CG, Varambally S, Chinnaiyan AM (2008) Repression of E-cadherin by the Polycomb group protein EZH2 in cancer. Oncogene 27(58):7274-7284. doi: 10.1038/onc.2008.333
24. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM (2002) The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907):624-629. doi: 10.1038/nature01075
25. Cimino-Mathews A, Hicks JL, Illei PB, Halushka MK, Fetting JH, De Marzo AM, Park BH, Argani P (2012) Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. Hum Pathol 43(7):1003-1011. doi: 10.1016/j.humpath.2011.08.007
26. Singhi AD, Cimino-Mathews A, Jenkins RB, Lan F, Fink SR, Nassar H, Vang R, Fetting JH, Hicks J, Sukumar S, De Marzo AM, Argani P (2012) MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod Pathol 25(3):378-387. doi: 10.1038/modpathol. 2011.171
27. Pal A, Huang W, Li X, Toy KA, Nikolovska-Coleska Z, Kleer CG (2012) CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer. Cancer Res 72(18):4818-4828. doi: 10.1158/0008-5472.CAN-12-0154
28. Cuadrado A, Nebreda AR (2010) Mechanisms and functions of p38 MAPK signalling. Biochem J 429(3):403-417. doi: 10.1042/BJ20100323
29. Drasin DJ, Robin TP, Ford HL (2011) Breast cancer epithelial-to- mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res 13(6):226. doi: 10.1186/bcr3037
30. Tiwari N, Gheldof A, Tatari M, Christofori G (2012) EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22(3):194-207. doi: 10.1016/j.semcancer.2012.02.013
31. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871-890. doi: 10.1016/j.cell.2009.11.007
32. Hong J, Zhou J, Fu J, He T, Qin J, Wang L, Liao L, Xu J (2011) Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness. Cancer Res 71(11):3980-3990. doi: 10.1158/0008-5472.CAN-10-2914
33. Hipp S, Berg D, Ergin B, Schuster T, Hapfelmeier A, Walch A, Avril S, Schmalfeldt B, Hofler H, Becker KF (2010) Interaction of Snail and p38 mitogen-activated protein kinase results in shorter overall survival of ovarian cancer patients. Virchows Arch 457(6):705-713. doi: 10.1007/s00428-010-0986-5
34. Zohn IE, Li Y, Skolnik EY, Anderson KV, Han J, Niswander L (2006) p38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. Cell 125(5):957-969. doi: 10.1016/j.cell.2006.03.048
35. Parvani JG, Taylor MA, Schiemann WP (2011) Noncanonical TGF-beta signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia 16(2):127-146. doi: 10.1007/s10911-011-9207-3
36. Hsieh YH, Wu TT, Huang CY, Hsieh YS, Hwang JM, Liu JY (2007) p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res 67(9):4320-4327. doi: 10.1158/0008-5472.CAN-06-2486
37. Junttila MR, Ala-Aho R, Jokilehto T, Peltonen J, Kallajoki M, Grenman R, Jaakkola P, Westermarck J, Kahari VM (2007) p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 26(36):5267-5279. doi: 10.1038/sj.onc.1210332
38. Demuth T, Reavie LB, Rennert JL, Nakada M, Nakada S, Hoelzinger DB, Beaudry CE, Henrichs AN, Anderson EM, Berens ME (2007) MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol Cancer Ther 6(4):1212-1222. doi: 10.1158/1535-7163.MCT-06-0711
39. Hsieh MJ, Chen KS, Chiou HL, Hsieh YS (2010) Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway. Eur J Cell Biol 89(8):598-606. doi: 10.1016/j.ejcb.2010.03.004
40. Johansson N, Ala-aho R, Uitto V, Grenman R, Fusenig NE, Lopez-Otin C, Kahari VM (2000) Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J Cell Sci 2:227-235
41. Kumar P, Yadav A, Patel SN, Islam M, Pan Q, Merajver SD, Teknos TN (2010) Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Mol Cancer 9:206. doi: 10.1186/1476-4598-9-206
42. Xu L, Chen S, Bergan RC (2006) MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 25(21):2987-2998. doi: 10.1038/sj.onc.1209337
43. Park SY, Jeong KJ, Panupinthu N, Yu S, Lee J, Han JW, Kim JM, Lee JS, Kang J, Park CG, Mills GB, Lee HY (2011) Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 30(11):1351-1359. doi: 10.1038/onc.2010.517
44. Dreissigacker U, Mueller MS, Unger M, Siegert P, Genze F, Gierschik P, Giehl K (2006) Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. Cell Signal 18(8):1156-1168. doi: 10.1016/j.cellsig.2005.09.004
45. Loesch M, Chen G (2008) The p38 MAPK stress pathway as a tumor suppressor or more? Front Biosci 13:3581-3593
46. Lee ST, Li Z, Wu Z, Aau M, Guan P, Murthy Karuturi RK, Liou YC, Yu Q (2011) Context-specific regulation of NF-kB target gene expression by EZH2 in breast cancers. Mol Cell 43:789-810